Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial

Last updated: February 13, 2013
Sponsor: Mayo Clinic
Overall Status: Completed

Phase

3

Condition

Myasthenia Gravis (Chronic Weakness)

Amyotrophic Lateral Sclerosis (Als)

Scar Tissue

Treatment

N/A

Clinical Study ID

NCT00035815
1461-01
R01NS042759
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place at approximately 6-month intervals.

Eligibility Criteria

Inclusion

Inclusion Criteria Patients entering this study:

  • Are between the ages of 18-80 years old.

  • Legal residents of the United States or Canada.

  • Have a history of a chronic onset of a progressive motor weakness of less than 24months duration.

  • Fulfill El Escorial criteria of probable or definite ALS.

  • If female, are surgically sterile, two years postmenopausal, or if of child-bearingpotential, must be using a medically acceptable method of birth control and agree tocontinue use of this method for the duration of the study. Acceptable methods includea barrier method with spermicide, oral contraceptives (normal doses are acceptable;low dose oral contraceptives or contraceptive implants must be used with a barriermethod), intrauterine device (IUD), or abstinence. Have a negative pregnancy test.

  • Are able to comply with protocol requirements.

  • Can provide written informed consent.

  • Have a manual muscle testing score of less than 8.

  • Have a forced vital capacity by pulmonary function testing *60% predicted.

Exclusion

Exclusion Criteria: Patients entering this study will not:

  • Have any of the following conditions:renal disease (Creatine > 2.0) or other activesystemic disease

  • Have any clinically significant abnormalities on the prestudy laboratory evaluation,physical examination, ECG, chest x-ray or ophthalmologic exam.

  • Have any clinically significant medical condition (e.g., within six months ofbaseline, had myocardial infarction, angina pectoris, and/or congestive heart failure)that, in the opinion of the investigator, would compromise the safety of patient.

  • Have Type I or Type II diabetes.

  • Have a history of cancer including melanoma with the exception of localized skincancers (with no evidence of metastasis, significant invasion, or re-occurrence withinthree years of baseline) and carcinoma in-situ of the cervix (women only).

  • Have used an investigational drug within 30 days of baseline visit.

  • Have had a tracheostomy.

  • Have a Beck's Depression Inventory score * 12.

  • Have legal residency outside of the United States or Canada.

  • Be pregnant or breast-feeding.

Study Design

Total Participants: 330
Study Start date:
June 01, 2003
Estimated Completion Date:
December 31, 2007

Study Description

The objective of this trial was to determine whether IGF-1 (MyotrophinTM) slows progression of weakness in amyotrophic lateral sclerosis (ALS). Three hundred thirty patients with ALS from 20 medical centers participated in this double blind, placebo-controlled two-year study. Half the patients received IGF-1 and the other half received placebo. The drug will be administered twice a day.

ALS is a neurodegenerative disorder that causes progressive muscle weakness and loss of motor neurons. IGF-1 is a neurotrophic factor essential for normal development of the nervous system and shows protection of motor neurons in animal models and cell culture systems. It is thought to block cell death pathways and promote muscle re-innervation and axonal growth and regeneration.

Connect with a study center

  • University of Puerto Rico

    San Juan, 00935
    Puerto Rico

    Site Not Available

  • Mayo Clinic in Scottsdale

    Scottsdale, Arizona 85259
    United States

    Site Not Available

  • California Pacific Medical Center

    San Francisco, California 94115
    United States

    Site Not Available

  • Mayo Clinic in Jacksonville

    Jacksonville, Florida 32224
    United States

    Site Not Available

  • Emory University

    Atlanta, Georgia 30322
    United States

    Site Not Available

  • Indiana University

    Indianapolis, Indiana 46202
    United States

    Site Not Available

  • University of Michigan Medical Center

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • Henry Ford Hospital

    Detroit, Michigan 48202
    United States

    Site Not Available

  • Hennepin County Medical Center

    Minneapolis, Minnesota 55404
    United States

    Site Not Available

  • Mayo Clinic

    Rochester, Minnesota 55905
    United States

    Site Not Available

  • University of Mississippi

    Jackson, Mississippi 39216
    United States

    Site Not Available

  • Beth Israel Medical Center

    New York, New York 10003
    United States

    Site Not Available

  • University of Rochester Medical Center

    Rochester, New York 14642
    United States

    Site Not Available

  • University of Cincinnati

    Cincinnati, Ohio 45219
    United States

    Site Not Available

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • Ohio State University

    Columbus, Ohio 43210
    United States

    Site Not Available

  • University of Pennsylvania, Pennsylvania Hospital

    Philadelphia, Pennsylvania 19107
    United States

    Site Not Available

  • Methodist Hospital

    Houston, Texas 77030
    United States

    Site Not Available

  • West Virginia University

    Morgantown, West Virginia 26506
    United States

    Site Not Available

  • Froedtert and Medical College Clinics

    Milwaukee, Wisconsin 53226
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.